• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Es werden Arzneimittelzubereitungen in Form stabiler Lösungen oder von Lyophilisaten von Oxicam-Derivaten der in welcher R einen heterocyclischen Ring, wie z.B. Pyridin oder 5-Methyl-3-isoxazol bedeutet und X zusammen mit Y einen ankondensierten aromatischen Ring, wie z.B. den Benzol- oder Thiophenring darstellt, beschrieben. Die Stabilität auch bei hoher Konzentration wird erreicht durch einen mehr als einmolaren Zusatz einer Base der Formel II in welcher R ein Wasserstoffatom oder eine Alkylgruppe mit 1-6 Kohlenstoffatomen und n die Zahlen 3 oder 4 bedeutet. Zur Herstellung von langzeitstabilen Injektionslösungen wird ein physiologisch unbedenkliches Lösungsmittel zugegeben. Die Lösungen eignen sich zur parenteralen, insbesondere zur intraartikulären Injektion und zur Gefriertrocknung und zeichnen sich durch besondere Verträglichkeit aus.
    公开号:SU1295993A3
    申请号:SU833589549
    申请日:1983-05-05
    公开日:1987-03-07
    发明作者:Гебхардт Уве；Аугарт Гельмут；Кнехт Адольф
    申请人:Гедеке Аг,Западный Берлин (Фирма)；
    IPC主号:
    专利说明:

    112
    This invention relates to the chemical and pharmaceutical industry and concerns the production of anti-inflammatory agents.
    The purpose of the invention is to increase the stability of the agent by using another organic base.
    The proposed method allows to prepare highly concentrated stable preparations with the content of the active substance up to 30%. The resulting solutions, even when stored for 15 months, do not show any precipitation of the active substance.
    The preparation obtained according to the second variant of the method is a lyophilisate which, after adding an appropriate amount of water, immediately dissolves and gives (also in the absence of organic solvents) a clear solution that is stable for at least 30 minutes.
    Freezing and freeze drying is carried out in a known manner.
    Example 1 A. 10.75 g of methyl glucamine dissolved in 30 g of diststitylglucamine is
    35
    molten water. To this no-: jg solution of isoxicam and piroxicam, 15 g of isoxicants (R-5-methyl-3-isoxazole; X and Y-benzene) and 30 g of polyethylene glycol (PEG) with an average of a pier 200, with the ratio of isoxicam and methyl glucamine being 1: 1, 23, heated at 60-70 ° C until complete dissolution. After cooling, add distilled water to 100 ml and filter through a membrane filter with an opening size of 0.22 µm. The transparent solution thus obtained, containing 26.67% by volume of GOG, is filled with 1 ml transparent ampoules containing 15 ml of isoxacam.
    Similarly receive solutions containing the following components, g (% of the volume of the solution):
    40
    45
    Methylglucamine Isoxicam PEG 200
    Distilled water
    Methylglucamine Isoxicam PEG 200
    Distilled water
    10.7550
    15.0
    20.0 (17.78)
    Up to 100.0 ml
    10.7555
    15.0
    10.0 (8.89)
    Up to 100.0 ml
    Ethylglucamine Isoxicam PEG 200 Distilled water Ethylglucamine Isoxicam PEG 200 Distilled water Ethylg Lucamin Isoxicam PEG 200 Distilled water Ethylglucamine Isoxicam PEG 200 Distilled water
    5.76 7.50 15.0
    1, 23. Molar ratio of active substance and glucamine derivative 1:, 23
    To 50.00ml 6.08 7.50 15.00
    Up to 50.00 ml
    7.02
    7.50
    15.0
    To 50.00 ml 9.36 7.50 15.00
    Up to 50.00 ml
    1: 1.30
    1: 1.50
    ; 2.00
    50
    five
    G. Methylg Lucamine Isoxicam PEG 300 Distilled Water
    D. Methylglucamine Isoxicam PEG 400 Distilled Water
    E. Methylglucamine Isoxicam Dimethylacetamide Distilled water
    G. Methylglucamine Piroxicam (and - pyridine; X and Y - benzene) PEG 200
    Distilled water
    3. Methylglucamine Piroxicam Dim e tilace t amide Distilled water
    10.75
    15.0
    20.0 (17.78)
    Up to 100.0 ml
    10.75
    15.0
    10.0 (8.89)
    Up to 100.0 ml
    10.75
    15.0
    30.0 (31.81)
    Up to 100.0 10.75
    ml
    14.84
    30.0 (26.67)
    Up to 100.0 ml
    10.75
    14.84
    30.0 (31.81)
    Up to 100.0 ml
    I
    In solutions of B-3, the molar ratio-to-glucamine is
    five
    g isoxacam and piroxicam
    0
    five
    0
    five
    Ethylglucamine Isoxicam PEG 200 Distilled water Ethylglucamine Isoxicam PEG 200 Distilled water Ethylg Lucamin Isoxicam PEG 200 Distilled water Ethylglucamine Isoxicam PEG 200 Distilled water
    5.76 7.50 15.0
    1, 23. Molar ratio of active substance and glucamine derivative 1:, 23
    To 50.00ml 6.08 7.50 15.00
    Up to 50.00 ml
    7.02
    7.50
    15.0
    To 50.00 ml 9.36 7.50 15.00
    Up to 50.00 ml
    1: 1.30
    1: 1.50
    ; 2.00
    . Methylgluc-min
    Sudoxnkam (R - 2-thiazole; X and Y -. Benzene) PEG 200 Distilled water
    . Ethylglucamine 5.83 Piroxicam 7.50 PEG 200 Distilled Water
    . Ethylglucamine 5.76 Isoxicam 7.50 Dimethyl Acetamide
    Distilled water
    . Ethylglucamine 5.76 Isoxacam 7.50 PEG 400 Distilled Water
    , Ethylglucamine 5.15 Isoxicam 7.50 PEG 200 Distilled water
    . Ethylglucamine 5.76 Isoxacam 7.50 PEG 300 Distilled Water
    . n-propyl glucose izoksikam PEG 200 Distilled water
    5.34
    7.50 15.00
    Up to 50.00 ml
    15.00
    Up to 50.00 ml
    5.76
    7.50
    15.00
    To 50.00 ml 5.76 7.50 15.00
    Up to 50.00 ml 5.15 7.50 15.00
    To 50.00 ml 5.76 7.50 15.00
    Up to 50.00 ml
    6.14 7.50 15.00
    1.23
    1: 1.23
    1: 1.23
    1: 1.23
    1: 1,1
    1: 1.23
    1: 1.23
    fO
    f5
    20
    25
    Up to 50.00 ml
    In solutions of I - O and P - Y, the content of polyethylene glycol is 6.67% by volume, and solution P contains 1.81% by volume of dimethylacetamide. Ampoules, 45 observant solutions A – Y, are stored at ambient temperature for 14 hours. After this time, the amules are visually examined for the presence of solution turbidity. Result: in these ampoules there is no turbidity.
    35
    0
    40
    Example 2 (comparative). Example 1A, 1ZH and 1H are repeated, with the difference that in all cases the active substance and methyl glucamine are used in an equimolar ratio. However, after 14 days of storage, the solutions are cloudy.
    O
    five
    0
    five
    five
    Comparison of the results of the examples and 2 indicates that the purpose of the invention is not achieved by observing the lower limit of the molar ratio of the active distribution and the organic base.
    Example 3. Example 1A is repeated, with the difference that a solution is prepared containing 15.0 g of isoxicam, 23.4 g of ethylglucamine (molar ratio 1: 2.5) and 30 g (26.67% by volume A) PEG, the heating being carried out at.
    The solution is filled with clear vials that are stored for 30 days. In this case, the turbidity of the solution is not observed.
    Example 4. Example 1A is repeated, with the difference that a solution containing 5 vol% PEG is prepared. The solution is filled with clear vials that are stored at room temperature for 14 days. After this time, the ampoules are visually examined for the presence of turbidity of the solution. Result: no turbidity.
    Example 5 (comparative). Example 4 is repeated with the difference that a solution is prepared containing 4% by volume of PEG. At the same time, after 14 days of storage, a slight turbidity of the solution is observed. Comparison of the results of examples 4 and 5 shows that, if 5 is not observed, the lower limit of the amount of water-miscible organic solvent can not be achieved.
    Example 6. Example 1A is repeated, with the difference that a solution is prepared containing 15.0 g of isoxicam, 23.4 g of ethylglucamine (molar ratio 1: 2.5) and 78.7 g (70% by volume PEG. The solution is filled into clear vials that are stored at room temperature for 40 days. In this case, the turbidity of the solution is not observed.
    Example 7. 10.75 g of methyl glucose are dissolved in 20 g of distilled water. After adding 15 g of isoxicam PEG with an average mol.m.
    200 (PEG 200) are added to 100 ml. In this case, the molar ratio of isoxicam and methylglucamine is 1:: 1.23, and the content of PEG is 48.2% by volume. The mixture is heated at 40 ° C until complete dissolution, after cooling the filter
    five
    through a 0.22 µm filter and filled with 1 ml clear ampoules. After 14 days of storage at room temperature, turbidity of the solution is not observed.
    Example 8. Example 7 is repeated with the difference that a solution is prepared containing 11.52 g of ethyl glucamine, 15.0 g of isoxicam, 20 g of distilled water and up to 100 ml of PEG 200. The molar ratio of isoxicam and ethyl glucamine is 1:: 1.23, and the content of PEG 47.5% by volume. After 14 days of storage at room temperature, no cloudiness of the solution was observed.
    Example 9 13.1 g of methylglucamine are dissolved in 50 ml of distilled water. After addition of 15.0 g of isoxicam, distilled water is added to 100 ml. At the same time, the molar ratio of ieoxicam and methyl20 mer 9, with the difference that a mixture containing 12.64 g of ethylglucamine and 15.0 g of isoxicam (molar ratio of 1.35: 1) is prepared, is heated at 40 ° C to dissolving.
    Glucamine is 1: 1.5. After stirring, the mixture is heated at 80 ° C to a full- 25 Prepared injection solution for the dissolving leg. After cooling, it remains transparent for 30 minutes. 30 C is filtered through a membrane
    No solid precipitation is observed.
    Example 13 (comparative).
    for freeze-drying with temp. jq. Example 9 is repeated with the difference that
    methylglugokamine and isoxicam are used at an equimolar ratio. At the same time, the resulting injection solution becomes turbid after 5 minutes, and after 30 minutes it remains transparent and not in it, after 10 minutes, precipitation is observed; solid deposition of the solid is observed.
    filter with a hole size of 0.22 microns. 1 ml of solution is placed in a container
    From -40 to -50 ° C, they are frozen and then freeze-dried. An injection solution is prepared by adding 1 ml of water.
    the company.
    Example 10. Example 9 is repeated with the difference that a lyophilisate is prepared using isoxicam and ethyl glucamine in a molar ratio of 1: 1.4. The resulting injection solution remains clear for 30 minutes. In addition, no solid precipitation is observed.
    Example 11. 528.5 g of methylglucamine are dissolved in 2000 g of distilled water with stirring, and a mixture of .667.5 g (11.9% by volume) of PEG with an average mol. 200 and 1136.5 g distilled water, as well as 667.5 g of isoxicam. The mixture is then heated at 70 ° C. 55 solution containing 18.72 g of ethyl- After complete dissolution of isoxicam glucamine and 15.0 g of isoxicam (mol p- is cooled to room temperature and its ratio is 2 to 2: 1). The resulting filter is injected. The filtrate is mixed with the clarified solution to remain a clear gel until a clear gel is obtained. within 40 min, and after 45 min

    Dp of this 77 g of carboxyvinyl polymer (carbopol 940) is suspended in distilled water and dispersed to the absence of lumps. The resulting dispersion is mixed with a solution of 238.7 g of methylglucamine in 600 g of distilled water to form a clear gel.
    The resulting clear gel, dl
    Preparations for which isoxicam and methyl glucamine are used in a 1: 2 molar ratio are stored at room temperature for 14 days. After this time, visually examined for blistering and clotting. education.
    Result: no clouding and lumpiness.
    Example 12. Example 9 is repeated, with the difference that a mixture containing 12.64 g of ethyl glucamine and 15.0 g of isoxicam (molar ratio 1.35: 1) is prepared, and it is heated at 40 ° C until complete dissolution.
    25 The prepared injection solution remains clear for 30 minutes.
    Example 14 (comparative). Example 12 is repeated with the difference that a mixture is prepared that contains
    ethylglucamine and isoxicam in a 1.2: 1 molar ratio. The resulting injection solution remains clear only for 6 minutes, and after 10 minutes a solid precipitates.
    A comparison of the results of examples 9 and 12-14 shows that, if the lower limit of the molar ratio of the organic base and the active substance is not observed, the purpose of the invention is not achieved.
    Example 15. Example 9 is repeated with the difference that it prepared 7j
    solid precipitation is observed.
    Example 16 (sravntelnsh). Example 15 is repeated, with the difference that they prepare a solution containing ethylglucamine and isoxicam in a molar ratio of 2.1: 1. The resulting injection solution remains clear for 40 minutes, and after 45 minutes a solid precipitate is observed.
    A comparison of the results of examples 15 and 16 indicates that exceeding the upper limit of the molar ratio does not lead to an increase in the positive effect.
    Example 17 (known method A, 250 mg of isoxicam as the methylglucamine salt is dissolved in 15 ml of distilled water. To the resulting solution, 96.0 mg of sodium chloride is added and 25 ml of distilled water is added. After filtration through a membrane filter with the size The openings of the 0.22 µm solution are filled into transparent ampoules with a capacity of 1 ml. After 30 seconds after filling, the solution becomes cloudy.
    B. 250 mg sudoxicam as a methylglucamine salt is dissolved in 15 ml of distilled water. To the resulting solution was added 97.0 mg of sodium chloride and 25 ml of distilled water. After filtering through a 0.22 µm membrane filter, the solution is filled into 1 ml transparent ampoules. After 25. seconds after filling, the solution becomes cloudy.
    B. 250 mg of piroxicam as the methylglucamine salt is dissolved in 15 ml of distilled water. To the resulting solution, 95.0 mg of sodium chloride and distilled




    A 1m opening of 0.22 µm solution was filled with 1 ml transparent ampoules. 30 seconds after filling, the solution becomes cloudy.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    A method for producing an agent based on 4-hydroxy-2H 1,2-benzothiazine-3-carboxamide-1,1-dioxide derivatives by dissolving 4-hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1 derivatives - dioxide of general formula
    CO-NH-R
    where R is 5-methyl-3-isoxazole,. pyridine and 2-thiazole, in distilled water in the presence of an organic base, followed by filtration and amputation, characterized in that, in order to increase the stability of the agent, a compound of the general formula is used as the organic base
    R —NH — CH - (CHOH) —CH, OH,
    where R is an alkyl group with 16 carbon atoms; p 3 or 4, dissolving is carried out at a ratio of active substance and organic base 1: 1.1-2.5, water-miscible organic solvent, polyethylene glycol, is added in an amount of 5-70% by volume and heated at 40-80 ° C. or the active substance and the organic base are mixed in a molar ratio of 1: 1.35-2 and heated,
    add water to 25 ml. After f-45 at the same temperature and after amputation through a membrane filter with dilution, the solution is lyophilized.
    Editor V. Petrash
    Compiled by A. Modl Techred L. Oleinik
    Order 629/63 Circulation 596 Subscription
    VNSHPI USSR State Committee
    for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
    Production and printing company, Uzhgorod, st. Project, 4
    Proofreader O. Lugova
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1295993A3|1987-03-07|Method of producing 4-oxy-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide derivative-base agent
    Scartazzini et al.1988|Organogels from lecithins
    KR100517643B1|2005-09-28|Thermosensitive poly|, preparation method thereof and injectable thermosensitive polyphosphazene hydrogels using the same
    DE60132108T2|2008-12-11|FREEZER-DRIED PANTOPRAZOLE PREPARATION AND PANTOPRAZOLE INJECTION
    SE454842B|1988-06-06|COMPOSITION FOR APPLICATION FOR Ophthalmological applications containing an aqueous solution of a high molecular weight polymer and a loose polymeric substance
    FI87993B|1992-12-15|FOER REFRIGERATION FOR ALKALIS INJECTION TORASEMID INNEHAOLLANDE VATTEN, SOM AER FAERDIGA FOER INJICERING
    AU2017231022A1|2018-10-25|Methods of forming ionically cross-linked gels
    Arisaka et al.1979|Reassembly of the bacteriophage T4 tail from the core-baseplate and the monomeric sheath protein P18: a co-operative association process
    RU2313346C2|2007-12-27|Pharmaceutical composition
    CN102188367B|2012-11-07|Insulin glargine injecta and preparation method thereof
    FR2482458A1|1981-11-20|ANTITUMOR COMPOSITIONS BASED ON METHANESULFON-M-ANISIDINE
    RU2011658C1|1994-04-30|Method of aromatic polyamide solution preparing
    US4133879A|1979-01-09|Process for producing stable solutions of a sulphonamide and a potentiator
    KR920006911B1|1992-08-22|Process for preparing stablized injectable piroxicam composition
    CN1149091A|1997-05-07|Storage-stable liquid brightener formulations
    EP0318906B1|1992-05-13|Lyophilized preparation of platinum compound
    FR2740973A1|1997-05-16|NOVEL FORM OF HYDROXOCOBALAMINE ADMINISTRATION AND USE IN CYANOSIUM INTOXICATIONS
    RU2096043C1|1997-11-20|Antihypoxic agent and method of its preparing
    DE343323C|
    US3231539A|1966-01-25|Process for the manufacture of spinning solutions of poly-beta-lactams by dissolving in an alcoholic solution of calcium thiocyanate
    Krauss1918|The preparation of dichloramin T. and chlorinated eucalyptol 1. 2
    SU933674A1|1982-06-07|Spinning solution for making fibers
    PL66343B1|1972-06-30|
    FR2937259A1|2010-04-23|CATANIONIC VESICLES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATIONS
    SU1687587A1|1991-10-30|Method of increasing stability of solutions of mixtures of cellulose or acetyl cellulose with non-compatible synthetic polymers
    同族专利:
    公开号 | 公开日
    DE3373414D1|1987-10-15|
    NO831610L|1983-11-09|
    AU1366483A|1983-11-10|
    KR900008441B1|1990-11-22|
    DE3217315A1|1983-11-10|
    HU197208B|1989-03-28|
    EP0093999A2|1983-11-16|
    PH24334A|1990-05-29|
    DK157731C|1990-07-16|
    NO163314B|1990-01-29|
    EP0093999B1|1987-09-09|
    IL68421D0|1983-07-31|
    IL68421A|1986-04-29|
    ZA832816B|1983-12-28|
    AR230634A1|1984-05-31|
    DK204683A|1983-11-09|
    YU90383A|1988-02-29|
    FI831534A0|1983-05-04|
    IE830785L|1983-11-08|
    NZ204086A|1986-02-21|
    FI831534L|1983-11-09|
    JPH0257049B2|1990-12-03|
    KR840004509A|1984-10-22|
    CA1204668A|1986-05-20|
    NO163314C|1990-05-09|
    DE3217315C2|1986-05-22|
    ES522107A0|1984-06-01|
    PH22726A|1988-11-28|
    FI79944C|1990-04-10|
    JPS5931713A|1984-02-20|
    US4482554A|1984-11-13|
    ES8405274A1|1984-06-01|
    IE54729B1|1990-01-17|
    AU551337B2|1986-04-24|
    FI79944B|1989-12-29|
    DK204683D0|1983-05-06|
    DK157731B|1990-02-12|
    EP0093999A3|1985-05-15|
    DD211484A5|1984-07-18|
    GR77503B|1984-09-24|
    AT29383T|1987-09-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    BE629650A|1967-05-18|1900-01-01|
    JPS4931815A|1972-07-27|1974-03-22|
    SE421792B|1976-01-12|1982-02-01|Pfizer|PROCEDURE FOR PREPARING N- -4-HYDROXY-2-METHYL-2H-1,2-BENZO-THIAZINE-3-CARBOXAMIDE-1,1-DIOXIDE|
    DE2756113A1|1977-12-16|1979-06-21|Thomae Gmbh Dr K|NEW 4-HYDROXY-2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE-1,1-DIOXIDES, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCTS CONTAINING THESE|DE3346526C2|1983-12-22|1986-12-11|A. Nattermann & Cie GmbH, 5000 Köln|Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases|
    DE3435843C2|1984-09-29|1988-10-27|Goedecke Ag, 1000 Berlin, De|
    DE3437232A1|1984-10-10|1986-04-17|Mack Chem Pharm|STABILIZED INJECTION SOLUTIONS FROM PIROXICAM|
    JPH0430634Y2|1985-06-10|1992-07-23|
    IT1207994B|1986-01-03|1989-06-01|Therapicon Srl|WATER SOLUBLE SALTS OF ANTI-INFLAMMATORY AND ANALGESIC ADAPTITY COMPOUNDS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS.|
    ES2038733T3|1987-12-04|1993-08-01|Asta Medica Ag|PROCEDURE FOR PREPARING AN INJECTABLE SOLUTION OF THIOCTIC ACID SALT WITH THROMETHANOL AND / OR BASIC AMINO ACIDS.|
    HU205550B|1990-11-27|1992-05-28|Egyt Gyogyszervegyeszeti Gyar|Process for producing pyroxycam solution of increased stability, free from effects damaging tussues|
    WO1992009268A1|1990-12-03|1992-06-11|Vestar, Inc.|Prevention of synovial adhesions|
    IT1283252B1|1996-03-15|1998-04-16|Pulitzer Italiana|SOLUTIONS OF PIROXICAM INJECTABLE BY PARENTERAL WAY|
    AU1885999A|1998-02-17|1999-08-30|Miciopharma Chemical Aktiengesellschaft|A watersoluble nimesulide adduct also for injectable use|
    US6369328B1|1998-03-14|2002-04-09|The Furukawa Electric Co., Ltd.|Heat dissipating device for transmission line, transmission line with heat dissipating device, and method for fitting heat dissipating device to transmission line|
    DE10030345A1|2000-06-20|2002-01-10|Boehringer Ingelheim Vetmed|Highly concentrated stable meloxicam solutions|
    US20020035107A1|2000-06-20|2002-03-21|Stefan Henke|Highly concentrated stable meloxicam solutions|
    DE10161077A1|2001-12-12|2003-06-18|Boehringer Ingelheim Vetmed|Highly concentrated stable meloxicam solutions for needleless injection|
    US8992980B2|2002-10-25|2015-03-31|Boehringer Ingelheim Vetmedica Gmbh|Water-soluble meloxicam granules|
    EP1568369A1|2004-02-23|2005-08-31|Boehringer Ingelheim Vetmedica Gmbh|Use of meloxicam for the treatment of respiratory diseases in pigs|
    DE102004021281A1|2004-04-29|2005-11-24|Boehringer Ingelheim Vetmedica Gmbh|Use of meloxicam formulations in veterinary medicine|
    DE102004030409A1|2004-06-23|2006-01-26|Boehringer Ingelheim Vetmedica Gmbh|New use of meloxicam in veterinary medicine|
    BRPI0617208A2|2005-09-30|2011-07-19|Boehringer Ingelheim Vetmed|pharmaceutical preparation containing meloxicam|
    JP5559339B2|2009-10-12|2014-07-23|ベーリンガーインゲルハイムフェトメディカゲゼルシャフトミットベシュレンクテルハフツング|Container for compositions containing meloxicam|
    US20110218191A1|2010-03-03|2011-09-08|Boehringer Ingelheim Vetmedica Gmbh|Use of meloxicam for the long term-treatment of kidney disorders in cats|
    AU2010347598B2|2010-03-03|2014-11-27|Boehringer Ingelheim Vetmedica Gmbh|Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats|
    US9795568B2|2010-05-05|2017-10-24|Boehringer Ingelheim Vetmedica Gmbh|Low concentration meloxicam tablets|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE3217315A|DE3217315C2|1982-05-08|1982-05-08|Medicinal preparations containing oxicam derivatives|
    [返回顶部]